Leap Therapeutics Inc. (LPTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 47 THORNDIKE STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments70,64365,500114,91652,0713,89116,284
Cash and cash equivalents70,64365,500114,91652,0713,89116,284
Business combination, contingent consideration, asset   1,18973185 
Other undisclosed current assets9542,4507691301651,038
Total current assets:71,59767,950116,87452,2744,24117,322
Noncurrent Assets
Operating lease, right-of-use asset257669459528 
Property, plant and equipment 520366512486
Deposits noncurrent assets9661,1082939801,099 
Deferred income tax assets   159179 
Other noncurrent assets  3090  1,542
Deferred tax assets, net124
Other undisclosed noncurrent assets 576 3451,984 
Total noncurrent assets:1,2282,4031,0372,0973,2071,752
TOTAL ASSETS:72,82570,353117,91154,3717,44819,074
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,42210,8099,5555,4648,0126,451
Accounts payable6,4655,6574,1892,7174,5713,579
Accrued liabilities5,9575,1525,3662,7473,4412,872
Deferred revenue    1,500 
Debt    408  
Other undisclosed current liabilities262416432 474 
Total current liabilities:12,68411,2259,9877,3728,4866,451
Noncurrent Liabilities
Long-term debt and lease obligation:   37144  
Liabilities, other than long-term debt 262 204159 
Financial instruments subject to mandatory redemption, settlement terms, share value, amount    204159 
Operating lease, liability 26237144 
Other undisclosed noncurrent liabilities   (37) 5523,448
Total noncurrent liabilities: 262373487113,448
Total liabilities:12,68411,48710,0247,7209,1979,899
Equity
Equity, attributable to parent60,14158,866107,88746,651(1,749)9,175
Common stock269988602415
Additional paid in capital459,591376,807371,638270,155193,319162,393
Accumulated other comprehensive income (loss)106128(267)(579)76302
Accumulated deficit(399,582)(318,168)(263,572)(222,985)(195,168)(153,535)
Total equity:60,14158,866107,88746,651(1,749)9,175
TOTAL LIABILITIES AND EQUITY:72,82570,353117,91154,3717,44819,074

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues   1,5001,500  
Gross profit:   1,5001,500  
Operating expenses(87,041)(56,763)(42,926)(30,039)(33,451)(30,751)
Operating loss:(87,041)(56,763)(41,426)(28,539)(33,451)(30,751)
Nonoperating income (expense)487(608)(379)738126(835)
Gain (loss), foreign currency transaction, before tax(13)(608)(379)738126(835)
Other nonoperating income 500     
Interest and debt expense  (54)(41)(39)(23)(19)
Loss from continuing operations before equity method investments, income taxes:(86,554)(57,425)(41,846)(27,840)(33,348)(31,605)
Other undisclosed income from continuing operations before income taxes5,1402,9761,2353244458,487
Loss from continuing operations before income taxes:(81,414)(54,449)(40,611)(27,516)(32,903)(23,118)
Income tax expense (benefit)  (147)2423(20)
Loss from continuing operations:(81,414)(54,596)(40,587)(27,514)(32,900)(23,138)
Loss before gain (loss) on sale of properties:(40,587)(27,514)(32,900)(23,138)
Other undisclosed net loss      
Net loss:(81,414)(54,596)(40,587)(27,514)(32,900)(23,138)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(81,414)(54,596)(40,587)(27,514)(32,900)(23,138)
Preferred stock dividends and other adjustments    (675)(359) 
Other undisclosed net loss available to common stockholders, basic    (9,399)  
Net loss available to common stockholders, basic:(81,414)(54,596)(40,587)(37,588)(33,259)(23,138)
Other undisclosed net loss available to common stockholders, diluted      (7,284)
Net loss available to common stockholders, diluted:(81,414)(54,596)(40,587)(37,588)(33,259)(30,422)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(81,414)(54,596)(40,587)(27,514)(32,900)(23,138)
Comprehensive loss:(81,414)(54,596)(40,587)(27,514)(32,900)(23,138)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(22)395312(655)(226)570
Comprehensive loss, net of tax, attributable to parent:(81,436)(54,201)(40,275)(28,169)(33,126)(22,568)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: